Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24028375 | 0.85 | EGFR (0.63) | EGFRCSF1RMAPTGRM1LCK | |
| SCHEMBL24028680 | 0.85 | GAK (0.50) | EGFRHTT | |
| SCHEMBL24028613 | 0.82 | EGFR (0.54) | EGFRCSF1RMAPTGRM1LCK | |
| SCHEMBL25616625 | 0.80 | MAP2K1 (0.47) | EGFRCSF1RMAPTERBB2SMN1; SMN2 | |
| SCHEMBL24028702 | 0.80 | MAP2K1 (0.58) | EGFRERBB2RAF1 | |
| SCHEMBL24028327 | 0.78 | KDR (0.47) | CSF1RLCKKDR | |
| SCHEMBL3320599 | 0.77 | EGFR (0.76) | EGFRCSF1RMAPTGRM1LCK | |
| SCHEMBL24028615 | 0.77 | EGFR (0.63) | EGFRCSF1RMAPTGRM1LCK | |
| SCHEMBL30416308 | 0.77 | EGFR (0.63) | EGFRCSF1RMAPTGRM1LCK | |
| SCHEMBL30417165 | 0.77 | EGFR (0.63) | EGFRCSF1RMAPTGRM1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2021231726-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | EGFR 4629/4885CSF1R 3641/4885MAPT 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.